← boardnext 2026-08next 2026-10
XENE
Xenon Pharmaceuticals Inc.distress 3/10 · well-funded / low risk$65.30-1%today-8% from 52w high
Neurology 1
Lead: major depressive disorder · target Kv7 · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$1340M
Runway
4.4 yrs
Shares 1y
+25%
Price & events
+54.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-2.5%
1W
+19.6%
1M
+17.8%
3M
+56.4%
6M
+109.4%
1Y
+49.2%
2Y
+256.8%
5Y
+343.0%
All
Overview
- Market Cap
- $6.31B
- Volume
- 17.62K
- 52 Week Range
- $30.30 – $70.96
- Total Shares
- 96.67M
- Float Shares
- 90.76M
- Short %
- 6.48%
- % Held by Insiders
- 0.13%
- % Held by Institutions
- 107.36%
- RVOL
- 0.01x
- Beta
- 0.61
Pipeline stages · 2 programs
Azetukalner
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
XEN1101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 9 trials · 8 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | Azetukalner | Major Depressive Disorder | — | recruiting |
| 2026-10 Estimated 50% readout ~2026-12-15 | Phase 3 | XEN1101 | Focal Onset Seizures | — | recruiting |
| 2027-01 Estimated 50% readout ~2027-03-17 | Phase 3 | Azetukalner | Major Depressive Disorder | — | enrolling by invitation |
| 2027-04 Estimated 50% readout ~2027-06-15 | Phase 3 | XEN1101 | Primary Generalized Tonic-Clonic Seizures | — | recruiting |
| 2027-05 Estimated 50% readout ~2027-07-15 | Phase 3 | Azetukalner | Major Depressive Disorder | — | recruiting |
Show all 9 trials · 4 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | Azetukalner | Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder | — | recruiting |
| 2029-06 Estimated 50% readout ~2029-08-15 | Phase 3 | Azetukalner | Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder | — | enrolling by invitation |
| 2033-04 Estimated 50% readout ~2033-06-15 | Phase 3 | XEN1101 | Focal Epilepsy, Tonic-Clonic Seizures | — | enrolling by invitation |
| 2026-01-12 | Phase 3 | XEN1101 | Focal Onset Seizures | 380 | completed |
Catalyst news & presentations · 24
- H1 2027Guided 55%readoutPhase 3azetukalner · Topline data from Phase 3 X-NOVA2 studySEC 8-K
- 2026Guided 40%enrollment completesecondaryPhase 3azetukalner · X-TOLE3 enrollment outside Japan expected to complete in 2026SEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)azetukalner · Anticipated NDA submission following X-TOLE2 dataSEC 8-K
- 2026Guided 40%readoutPhase 1XEN1120 · Phase 1 SAD/MAD study completion to support Phase 2SEC 8-K
- H2 2026Guided 55%trial initiationsecondaryPhase 2XEN1120 · Phase 2 proof-of-concept study expected to initiate after Phase 1 completionSEC 8-K
- H2 2026Guided 55%trial initiationsecondaryPhase 2XEN1701 · Phase 2 proof-of-concept study expected to initiate after Phase 1 completionSEC 8-K
- 2026Guided 40%readoutPhase 1XEN1701 · Phase 1 SAD/MAD study completion to support Phase 2SEC 8-K
- third quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)azetukalner · NDA submission to FDA for azetukalner in focal onset seizuresSEC 8-K
- 2026-08-10earningsEarningsEarnings releaseyahoo
- Sunday, April 19conferencedata presentationsecondaryazetukalner · Late Breaking Science oral presentation at AAN Annual MeetingSEC 8-K
- early 2026readoutPhase 3azetukalner · Topline data from X-TOLE2 studySEC 8-K
- 2025regulatory submissionFiled (NDA/BLA)Nav1.7 development candidate · IND filing for Nav1.7 programSEC 8-K
- 2025regulatory submissionFiled (NDA/BLA)Kv7 development candidate · IND filing for Kv7 programSEC 8-K
- second half of 2025readoutPhase 3azetukalner · Topline data from X-TOLE2 Phase 3 study in focal onset seizures.SEC 8-K
- Q3 2025trial initiationsecondaryPhase 1XEN1701 · Phase 1 study start for XEN1701SEC 8-K
- Q3 2025regulatory submissionFiled (NDA/BLA)XEN1701 · IND filing for XEN1701SEC 8-K
- August 30 to September 3, 2025conferencedata presentationsecondaryazetukalner · Four abstracts at 36th International Epilepsy CongressSEC 8-K
- mid-yeartrial initiationsecondaryPhase 3azetukalner · Initiation of first Phase 3 BPD studySEC 8-K
- first half of 2025readoutPhase 2azetukalner · Topline results from investigator-sponsored Phase 2 study in MDD at Mount Sinai.SEC 8-K
- 2025-02-27partnershipNBI-921355 · Phase 1 initiation triggers $7.5M milestone from NeurocrineSEC 8-K
- second half of 2024trial initiationsecondaryPhase 3azetukalner · First of three Phase 3 MDD trials expected to startSEC 8-K
- October 29 to November 2, 2024conferencedata presentationsecondaryazetukalner · Poster at Psych CongressSEC 8-K
- this quarterenrollment completesecondaryPhase 2azetukalner · Investigator-sponsored Phase 2 proof-of-concept study at Mount Sinai enrollment completionSEC 8-K
- September 7 to 11, 2024conferencedata presentationsecondaryazetukalner · Three posters at 15th European Epilepsy CongressSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-27JP MorganOverweight
- 2026-05-12JP MorganOverweight
- 2026-05-08RBC CapitalOutperform
- 2026-05-08NeedhamBuy
- 2026-03-16WedbushOutperform
- 2026-03-10Wells FargoOverweight
Competitors — Kv7
- BHVNBiohaven Ltd.$2.2B · D6
Recent news
- 2026-07-22Understanding the Setup: (XENE) and Scalable Risk - Stock Traders Daily
- 2026-07-19Xenon Pharmaceuticals (XENE) Stifel 2025 Healthcare Conference Summary - Quartr
- 2026-07-19Xenon Pharmaceuticals (XENE) Q1 2025 earnings summary - Quartr
- 2026-07-16Xenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial Execution - Seeking Alpha
- 2026-07-15Price to sales forward of Xenon Pharmaceuticals Inc. – GETTEX:XP0 - TradingView
- 2026-07-15Price to sales forward of Xenon Pharmaceuticals Inc. – TRADEGATE:XP0 - TradingView
- 2026-07-14Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds - Sahm
- 2026-07-13Price to sales forward of Xenon Pharmaceuticals Inc. – BIVA:XENE/N - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.